<DOC>
	<DOCNO>NCT02613871</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy , safety , tolerability ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) administer 12 week chronic genotype 1 2 HCV infect adult co-infected HBV Taiwan .</brief_summary>
	<brief_title>Safety Efficacy Ledipasvir/Sofosbuvir Fixed-Dose Combination Adults With Chronic HCV HBV Coinfection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Key Individuals chronic genotype 1 2 HCV HBV coinfection Individuals must take require treatment HBV antiviral therapy screening . For participant HBV treatment experience , recent treatment must complete least 6 month prior Day 1 . Cirrhosis determination Fibroscan Screening laboratory value within define threshold Use two effective contraception method female male childbearing potential Key Current prior history clinicallysignificant illness major medical disorder may interfere individual 's treatment , assessment compliance protocol Pregnant nursing female Infection human immunodeficiency virus ( HIV ) Hepatitis Delta virus ( HDV ) Hepatocellular carcinoma ( HCC ) malignancy Current prior history clinical hepatic decompensation Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>